Peregrine Pharmaceuticals (NASDAQ:PPHM) is a biopharmaceutical company that develops monoclonal antibodies for the treatment and diagnosis of cancer. The company has an extensive pipeline including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. PGN-650 is the company's PS-targeting imaging agent that represents a potential new approach to imaging cancer. In addition to these, the company has four investigator-sponsored trials looking at different treatment combinations.
In the past two weeks there have been a number of positive catalysts for the company:
1. On Wednesday, the Food and Drug Administration advanced Cotara as a treatment for glioblastoma, the most common and aggressive type of brain cancer, into the pivotal phase III trial. The company wants to compare two dose levels of the drug in up to 300 patients.
2. Healthcare-focused fund Ayer Capital Management, which is managed by Jay Venkatesen, recently bought 3.7 million shares of the stock.
3. Just last week, the stock price jumped above the red zone of under a dollar where it has been since September 24, 2012, when the company announced that it had discovered major discrepancies in treatment group of the bavituximab phase II second-line non-small cell lung cancer trial.
Although the stock trades at a low price, there still exists a lot of volume: an average of 3.9 million shares traded according to Google Finance. Right now I have a small position in the stock but plan to increase my position pending on results of Q2 2013 earnings to be reported this Monday after market close.
Disclosure: I am long PPHM. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.